Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / schedule-e-development-plan.docx
schedule-e-development-plan.docx
Parties
Penterra Pharmaceuticals Corp
Meridian Korea Inc
Meridian Bio Australia Pty Ltd
Alkerra Manufacturing Inc
PHARMACOVIGILANCE AND SA
Hong Kong SA
Macau SA
Dates
October 2, 2023
October 20, 2023
October 20, 2026
December 19, 2023
October 20, 2025
August 12, 2037
November 3, 2038
Amounts
$32,000,000
$6,000,000
$8,000,000
$10,000,000
$32,000,000 6.3
$18,000,000
$25,000,000
$45,000,000
$120,000,000
Obligations
Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement
All clinical development activities shall be conducted in a manner consistent with the global development strategy for PPC-4187, as coordinated through the JSC
In particular, Meridian acknowledges that the PMDA may require or recommend a supplemental pharmacokinetic/pharmacodynamic (PK/PD) bridging study in Japanese patients, and Meridian shall be prepared to conduct such a study concurrently with or as a pre-specified sub-study within Study PPC-4187-301, as further described in Section 3
shall serve as the overall clinical program lead for the Phase III development of PPC-4187 in the Licensed Territory
Morimoto shall be responsible for oversight of clinical trial design, conduct, and reporting, and shall serve as the primary point of contact for clinical development matters with the JSC
Clinical trial insurance and product liability coverage for all Phase III development activities in the Licensed Territory shall be provided by Jade Dragon Insurance Limited (Hong Kong), in accordance with the minimum coverage requirements specified in Section 12